Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351–7.
Article
CAS
PubMed
Google Scholar
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67.
Article
CAS
PubMed
Google Scholar
Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69(8):1002–10.
Article
PubMed
Google Scholar
Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease. Clin Neuropharmacol. 2012;35(1):25–9.
Article
CAS
PubMed
Google Scholar
Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, et al. Collaboration for Alzheimer’s prevention: principles to guide data and sample sharing in preclinical Alzheimer’s disease trials. Alzheimers Dement. 2016;12(5):631–2.
Article
PubMed
PubMed Central
Google Scholar
McDade E, Bateman RJ. Stop Alzheimer’s before it starts. Nature. 2017;547(7662):153–5.
Article
CAS
PubMed
Google Scholar
Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S. Development of interventions for the secondary prevention of Alzheimer’s dementia: the European Prevention of Alzheimer’s Dementia (EPAD) project. Lancet Psychiatry. 2016;3(2):179–86.
Article
PubMed
Google Scholar
Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33.
Article
PubMed
PubMed Central
Google Scholar
Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964–74.
Article
PubMed
Google Scholar
Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, et al. Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: results from a phase-3 study. J Nucl Med. 2016;57(6):900–6.
Article
CAS
PubMed
Google Scholar
Bullich S, Villemagne VL, Catafau AM, Jovalekic A, Koglin N, Rowe CC, et al. Optimal reference region to measure longitudinal amyloid-beta change with 18F-florbetaben PET. J Nucl Med. 2017;58(8):1300–6.
Article
CAS
PubMed
Google Scholar
Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H, et al. Optimized classification of 18F-florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin. 2017;15:325–32.
Article
PubMed
PubMed Central
Google Scholar
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424–35.
Article
CAS
PubMed
Google Scholar
Jennings D, Seibyl J, Sabbagh M, Lai F, Hopkins W, Bullich S, et al. Age dependence of brain beta-amyloid deposition in Down syndrome: an [18F] florbetaben PET study. Neurology. 2015;84(5):500–7.
Article
CAS
PubMed
Google Scholar
Tuszynski T, Rullmann M, Luthardt J, Butzke D, Tiepolt S, Gertz HJ, et al. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative beta-amyloid PET imaging to diagnose Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2016;43(6):1077–87.
Article
CAS
PubMed
Google Scholar
Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210–7.
Article
PubMed
Google Scholar
Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, et al. Comparison of 18F-florbetaben quantification results using the standard centiloid, MR-based, and MR-less CapAIBL((R)) approaches: validation against histopathology. Alzheimers Dement. 2019;15(6):807–16.
Article
PubMed
Google Scholar
Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chételat G, Raniga P, et al. (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res Ther. 2013;5(1):4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bischof GN, Jacobs HIL. Subthreshold amyloid and its biological and clinical meaning: long way ahead. Neurology. 2019;93(2):72–9.
Article
CAS
PubMed
Google Scholar
Fantoni E, Collij L, Lopes Alves I, Buckley C, Farrar G. AMYPAD consortium. The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging. J Nucl Med. 2020;61(2):166–71.
Article
CAS
PubMed
Google Scholar
Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ. In vivo staging of regional amyloid deposition. Neurology. 2017;89(20):2031–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging beta-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 2019;76(11):1319–29.
Collij LE, Heeman F, Salvadó G, Ingala S, Altomare D, de Wilde A, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020;95(11):e1538–53.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, et al. Topographical distribution of Abeta predicts progression to dementia in Abeta positive mild cognitive impairment. Alzheimers Dement (Amst). 2020;12(1):e12037.
PubMed Central
Google Scholar
Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, et al. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018;14(10):1281–92.
Article
PubMed
PubMed Central
Google Scholar
Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, Sanchez-Ruiz D, Abdelnour C, Valero S, et al. FACEHBI: a prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline. Study rationale and research protocols. J Prev Alzheimers Dis. 2017;4(2):100–8.
CAS
PubMed
Google Scholar
Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage. 2009;46(1):154–9.
Article
PubMed
Google Scholar
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273–89.
Article
CAS
PubMed
Google Scholar
Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129–35.
Article
CAS
PubMed
Google Scholar
Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1–15 e1–4.
Article
PubMed
Google Scholar
Rowe CC, Doré V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. 18F-Florbetaben PET beta-amyloid binding expressed in centiloids. Eur J Nucl Med Mol Imaging. 2017;44(12):2053–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Whittington A, Sharp DJ, Gunn RN. Spatiotemporal distribution of β-amyloid in Alzheimer disease is the result of heterogeneous regional carrying capacities. J Nucl Med. 2018;59(5):822–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41:479–86.
Article
CAS
PubMed
Google Scholar
Bullich S. Converging evidence for a “gray-zone” of amyloid burden and its relevance. in AAIC. 2020. Virtual.
Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27.
Article
PubMed
PubMed Central
Google Scholar
Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59(2):1152–60.
Article
PubMed
Google Scholar
La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 2019;15(2):205–16.
Article
PubMed
Google Scholar
Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(Pt 7):2020–33.
Article
PubMed
PubMed Central
Google Scholar
Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247–58.
Article
CAS
PubMed
Google Scholar
Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8(1):1214.
Article
PubMed
PubMed Central
CAS
Google Scholar
Guo T, Landau SM, Jagust WJ. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology. 2020;94(14):e1512–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Guo T, Dukart J, Brendel M, Rominger A, Grimmer T, Yakushev I. Rate of beta-amyloid accumulation varies with baseline amyloid burden: implications for anti-amyloid drug trials. Alzheimers Dement. 2018;14(11):1387–96.
Article
PubMed
Google Scholar
Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. Neuroanatomical spread of amyloid beta and tau in Alzheimer’s disease: implications for primary prevention. Brain Commun. 2020;2(1):fcaa007.
Article
PubMed
PubMed Central
Google Scholar
Lopes Alves I, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, et al. Quantitative amyloid PET in Alzheimer’s disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020;16(5):750–8.
Article
PubMed
PubMed Central
Google Scholar
Bullich S, Barthel H, Koglin N, Becker GA, De Santi S, Jovalekic A, et al. Validation of noninvasive tracer kinetic analysis of (18)F-Florbetaben PET using a dual-time-window acquisition protocol. J Nucl Med. 2018;59(7):1104–10.
Article
CAS
PubMed
Google Scholar